Bio-Techne (NASDAQ:TECH), specializes in developing, manufacturing, and selling innovative biotechnology products and services for the research and clinical diagnostic markets. The company's operations span a broad range of products including proteins, antibodies, assays, and reagents, which are fundamental for research in areas such as cancer, stem cell research, and immunology. Bio-Techne aims to empower researchers and clinicians around the globe with the tools and resources needed to advance scientific discovery and improve human health. The company's projects often involve collaborations with academic, governmental, and pharmaceutical organizations to develop new diagnostic and therapeutic methods. Objectives focus on maintaining high standards of quality, expanding their product portfolio, and geographic footprint, and staying at the forefront of biotechnological advancements.